%0 Journal Article
%T 乳腺癌相关治疗中细胞周期蛋白依赖性激酶4和6抑制剂机制相关的研究进展<br>Research Progress in the Related Mechanisms of Cyclin-Dependent Kinase 4 and 6 Inhibitors in the Treatment of Breast Cancer
%A 乌尔肯·别克拉米斯
%A 甫拉提·吾瓦力汗
%J Advances in Clinical Medicine
%P 18374-18381
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.13112580
%X 乳腺恶性肿瘤是世界上女性当中很常见的一类癌症，同时它的发病率和致死率每年都在上升。激素受体阳性(Hormone receptor positive type, HR+)乳腺癌及人表皮生长因子受体2阴性(human epi-dermal growth factor receptor 2-negative, HER2？)乳腺癌是最为常见的类型，内分泌治疗是它的主要治疗手段，同时药物出现耐药，影响疗效的情况也常发生。细胞周期蛋白依赖性激酶4和6 (cy-clin-dependent kinase 4 and 6, CDK4/6)抑制剂是一种细胞靶向药物，它与内分泌治疗药物的联合应用为HR+/HER2？乳腺癌患者提供了新的治疗方案，并且具有疗效好、副作用小等优点。尽管CDK4/6抑制剂在乳腺恶性肿瘤的治疗方面得到了很好的应用，但是它的分子生物学以及相关药理学方面的研究依然不断地在进行。现就以CDK4/6抑制剂相关作用机制、耐药机制方面予以综述。<br />
Breast malignancy is a very common type of cancer among women in the world, and its incidence and mortality are increasing every year. Hormone receptor positive type (HR+), Human epidermal growth factor receptor 2-negative (HER2？) breast cancer are the most common type, endocrine therapy is its main treatment, while drug resistance, the situation of affecting the efficacy also often occur. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are cell-targeted agents, and their combination with endocrine therapy agents offers a new treatment option for HR+/HER2？ breast cancer patients. It has the advantages of good curative effect and little side effect. Although CDK4/6 inhibitors have been well used in the treatment of breast malignant tumors, its molecular biology and related pharmacological studies are still ongoing. This article reviews the mechanism of action and drug resistance of CDK4/6 inhibitors.
%K 乳腺癌，CDK4/6抑制剂，耐药机制<br>Breast Cancer
%K CDK4/6 Inhibitor
%K Resistance Mechanism
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=76043